Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    Background: Recently, there has been a move toward decreasing the threshold for liver debulking for metastatic carcinoid tumors from 90% to 70%. The debulking threshold and factors that predict outcomes of liver debulking operations specifically among pancreatic neuroendocrine tumors are not well defined. Methods: Records of patients with pancreatic neuroendocrine tumors undergoing liver debulking with a threshold of 70% from 2006 to 2016 were reviewed. Extrahepatic metastases and positive margins by enucleation were allowed. Liver progression-free survival and overall survival were calculated by the Kaplan-Meier method for various factors and compared by log-rank. Factors also were correlated with liver progression-free survival and overall survival by multivariate regression analyses. Results: Forty-two patients underwent 44 operations, of which 24 resulted in 100% debulking, 12 resulted in ≥90% debulking, and 8 resulted in ≥70% debulking. Median liver progression-free survival was 11 months. The 5-year overall survival rate was 81%. There were no significant differences in outcome based on percent debulked. Only liver metastasis ≥5 cm correlated with liver progression-free survival and overall survival. Conclusion: Consideration should be given to expanding the criteria for liver debulking in pancreatic neuroendocrine tumors to include a new threshold of >70% debulking, intermediate grade tumors, positive margins, and extrahepatic metastases; these criteria yield results indistinguishable from complete resection. Using these expanded criteria will increase the number of patients eligible for an operation and maintain high survival rates.

    Original languageEnglish (US)
    JournalSurgery (United States)
    DOIs
    StateAccepted/In press - Jan 1 2017

    Fingerprint

    Neuroendocrine Tumors
    Neoplasm Metastasis
    Liver
    Disease-Free Survival
    Survival
    Survival Rate
    Carcinoid Tumor
    Multivariate Analysis
    Regression Analysis

    ASJC Scopus subject areas

    • Surgery

    Cite this

    @article{1dcc3a54d6254fbbada8392fddfac856,
    title = "Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors",
    abstract = "Background: Recently, there has been a move toward decreasing the threshold for liver debulking for metastatic carcinoid tumors from 90{\%} to 70{\%}. The debulking threshold and factors that predict outcomes of liver debulking operations specifically among pancreatic neuroendocrine tumors are not well defined. Methods: Records of patients with pancreatic neuroendocrine tumors undergoing liver debulking with a threshold of 70{\%} from 2006 to 2016 were reviewed. Extrahepatic metastases and positive margins by enucleation were allowed. Liver progression-free survival and overall survival were calculated by the Kaplan-Meier method for various factors and compared by log-rank. Factors also were correlated with liver progression-free survival and overall survival by multivariate regression analyses. Results: Forty-two patients underwent 44 operations, of which 24 resulted in 100{\%} debulking, 12 resulted in ≥90{\%} debulking, and 8 resulted in ≥70{\%} debulking. Median liver progression-free survival was 11 months. The 5-year overall survival rate was 81{\%}. There were no significant differences in outcome based on percent debulked. Only liver metastasis ≥5 cm correlated with liver progression-free survival and overall survival. Conclusion: Consideration should be given to expanding the criteria for liver debulking in pancreatic neuroendocrine tumors to include a new threshold of >70{\%} debulking, intermediate grade tumors, positive margins, and extrahepatic metastases; these criteria yield results indistinguishable from complete resection. Using these expanded criteria will increase the number of patients eligible for an operation and maintain high survival rates.",
    author = "Morgan, {Rosemary E.} and Pommier, {Su Ellen Johnson} and Rodney Pommier",
    year = "2017",
    month = "1",
    day = "1",
    doi = "10.1016/j.surg.2017.05.030",
    language = "English (US)",
    journal = "Surgery (United States)",
    issn = "0039-6060",
    publisher = "Mosby Inc.",

    }

    TY - JOUR

    T1 - Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors

    AU - Morgan, Rosemary E.

    AU - Pommier, Su Ellen Johnson

    AU - Pommier, Rodney

    PY - 2017/1/1

    Y1 - 2017/1/1

    N2 - Background: Recently, there has been a move toward decreasing the threshold for liver debulking for metastatic carcinoid tumors from 90% to 70%. The debulking threshold and factors that predict outcomes of liver debulking operations specifically among pancreatic neuroendocrine tumors are not well defined. Methods: Records of patients with pancreatic neuroendocrine tumors undergoing liver debulking with a threshold of 70% from 2006 to 2016 were reviewed. Extrahepatic metastases and positive margins by enucleation were allowed. Liver progression-free survival and overall survival were calculated by the Kaplan-Meier method for various factors and compared by log-rank. Factors also were correlated with liver progression-free survival and overall survival by multivariate regression analyses. Results: Forty-two patients underwent 44 operations, of which 24 resulted in 100% debulking, 12 resulted in ≥90% debulking, and 8 resulted in ≥70% debulking. Median liver progression-free survival was 11 months. The 5-year overall survival rate was 81%. There were no significant differences in outcome based on percent debulked. Only liver metastasis ≥5 cm correlated with liver progression-free survival and overall survival. Conclusion: Consideration should be given to expanding the criteria for liver debulking in pancreatic neuroendocrine tumors to include a new threshold of >70% debulking, intermediate grade tumors, positive margins, and extrahepatic metastases; these criteria yield results indistinguishable from complete resection. Using these expanded criteria will increase the number of patients eligible for an operation and maintain high survival rates.

    AB - Background: Recently, there has been a move toward decreasing the threshold for liver debulking for metastatic carcinoid tumors from 90% to 70%. The debulking threshold and factors that predict outcomes of liver debulking operations specifically among pancreatic neuroendocrine tumors are not well defined. Methods: Records of patients with pancreatic neuroendocrine tumors undergoing liver debulking with a threshold of 70% from 2006 to 2016 were reviewed. Extrahepatic metastases and positive margins by enucleation were allowed. Liver progression-free survival and overall survival were calculated by the Kaplan-Meier method for various factors and compared by log-rank. Factors also were correlated with liver progression-free survival and overall survival by multivariate regression analyses. Results: Forty-two patients underwent 44 operations, of which 24 resulted in 100% debulking, 12 resulted in ≥90% debulking, and 8 resulted in ≥70% debulking. Median liver progression-free survival was 11 months. The 5-year overall survival rate was 81%. There were no significant differences in outcome based on percent debulked. Only liver metastasis ≥5 cm correlated with liver progression-free survival and overall survival. Conclusion: Consideration should be given to expanding the criteria for liver debulking in pancreatic neuroendocrine tumors to include a new threshold of >70% debulking, intermediate grade tumors, positive margins, and extrahepatic metastases; these criteria yield results indistinguishable from complete resection. Using these expanded criteria will increase the number of patients eligible for an operation and maintain high survival rates.

    UR - http://www.scopus.com/inward/record.url?scp=85035068572&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85035068572&partnerID=8YFLogxK

    U2 - 10.1016/j.surg.2017.05.030

    DO - 10.1016/j.surg.2017.05.030

    M3 - Article

    C2 - 29103583

    AN - SCOPUS:85035068572

    JO - Surgery (United States)

    JF - Surgery (United States)

    SN - 0039-6060

    ER -